Comparative Pharmacology
Head-to-head clinical analysis: QDOLO versus TRAMADOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QDOLO versus TRAMADOL HYDROCHLORIDE.
QDOLO vs TRAMADOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
Tramadol hydrochloride is a centrally acting opioid analgesic that binds to μ-opioid receptors and inhibits the reuptake of norepinephrine and serotonin, modulating pain transmission in the central nervous system.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
50-100 mg orally every 4-6 hours as needed for pain, not to exceed 400 mg/day (100 mg for immediate-release).
None Documented
None Documented
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
5-6 hours (parent drug); 7-9 hours (M1 active metabolite). In renal impairment, half-life prolonged up to 11 hours (parent) and 17 hours (M1).
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Primarily renal (90% total clearance, 30% as unchanged drug, 60% as metabolites); fecal (~10%); biliary minor.
Category C
Category D/X
Opioid Agonist
Opioid Agonist